J Korean Med Assoc.  2013 Jul;56(7):576-582. 10.5124/jkma.2013.56.7.576.

Cardiovascular disease in end-stage renal disease

• Park JT
• Oh HJ
• Kang SW

• KMID: 2193047
• DOI: http://doi.org/10.5124/jkma.2013.56.7.576

Abstract

The number of end-stage renal disease (ESRD) patients is progressively growing with more than 60,000 ESRD patients on renal replacement therapy in Korea. The mortality risk in ESRD patients is approximately 10 to 20-fold higher compared to the general population, which is mainly attributed to prevalent cardiovascular disease in these patients. However, the risk factors for cardiovascular disease in ESRD patients are different from the general population, and useful biomarkers for predicting cardiovascular mortality are not completely defined. The nationwide multicenter Clinical Research Center (CRC) for ESRD program was initiated in Korea not only to elucidate the incidence and prevalence of cardiovascular disease in ESRD patients but also to identify potential risk factors including various biomarkers for cardiovascular disease. A prospective cohort of 864 incident hemodialysis patients, from 34 dialysis centers of the CRC for ESRD in Korea, was followed up for 36 months, and the clinical outcome of these patients was reviewed. This article presents the recent data from the CRC for ESRD program, and, in addition, brief reviews on key risk factors and potential biomarkers for cardiovascular disease in ESRD patients.

Keyword

Chronic kidney failure; Cardiovascular diseases; Risk factors; Biological markers

MeSH Terms

Biomarkers
Cardiovascular Diseases
Cohort Studies
Dialysis
Humans
Incidence
Kidney Failure, Chronic
Korea
Prevalence
Prospective Studies
Renal Dialysis
Renal Replacement Therapy
Risk Factors

Figure

• 

  Figure 1 Cause of death in end-stage renal disease patients. Cardiovascular disease is the most common cause of death in patients on hemodialysis and peritoneal dialysis in Korea (From Jin DC. Kidney Res Clin Pract 2012;31:62-71) [1]. liver dis, liver disease; PD, peritoneal dialysis; HD, hemodialysis.

Reference

1. Jin DC, Ha IS, Kim NH, Lee SW, Lee JS, Yoon SR, Kim BS. Brief report: renal replacement therapy in Korea. Kidney Res Clin Pract. 2012; 31:62–71.

2. Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol. 2008; 4:672–681.

3. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003; 63:793–808.

4. Hickman PE. Biomarkers and cardiac disease in patients with end-stage renal disease on dialysis. Clin Biochem Rev. 2011; 32:115–119.

5. The USRDS Dialysis Morbidity and Mortality Study: Wave 2. United States Renal Data System. Am J Kidney Dis. 1997; 30:2 Suppl 1. S67–S85.

6. Kim KS, Kim JG, Woo ST, Suh SY, Kim H, Kwon YJ, Pyo HJ, Kim YS, Cha DR, Jo WY, Kim HK, Kim CS, Park SE, Mun CH, Park KS, Kim MB, Koo JR. Factors contributing to mortality in chronic hemodialysis patients. Korean J Med. 1998; 54:355–362.

7. Kimmel PL, Varela MP, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Amarashinge A, Mishkin GJ, Cruz I, Veis JH. Interdialytic weight gain and survival in hemodialysis patients: effects of duration of ESRD and diabetes mellitus. Kidney Int. 2000; 57:1141–1151.

8. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl. 2003; (87):S24–S31.

9. Park J, Lertdumrongluk P, Molnar MZ, Kovesdy CP, Kalantar-Zadeh K. Glycemic control in diabetic dialysis patients and the burnt-out diabetes phenomenon. Curr Diab Rep. 2012; 12:432–439.

10. Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, McAllister CJ, Whellan D, Sharma K. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007; 30:1049–1055.

11. Li Z, Lacson E Jr, Lowrie EG, Ofsthun NJ, Kuhlmann MK, Lazarus JM, Levin NW. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis. 2006; 48:606–615.

12. Tozawa M, Iseki K, Iseki C, Takishita S. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int. 2002; 61:717–726.

13. Ryu DR, Ryu JH, Bae KS, Yu M, Lim JB, Kim SJ, Pyun WB, Choi KB, Shin GJ, Yoon KI, Kang DH. Effects of short-term partial correction of anemia in end-stage renal disease (ESRD) patients on maintenance hemodialysis: changes of amino-terminal pro B-type natriuretic peptide (NT-pro BNP) and echocardiographic parameters. Korean J Nephrol. 2006; 25:803–811.

14. Sikole A, Polenakovic M, Spirovska V, Polenakovic B, Masin G. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs. 1993; 17:977–984.

15. Cerasola G, Nardi E, Palermo A, Mule G, Cottone S. Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review. J Nephrol. 2011; 24:1–10.

16. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005; 16:2180–2189.

17. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339:584–590.

18. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990; 15:458–482.

19. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F. AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360:1395–1407.

20. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353:238–248.

21. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R. SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377:2181–2192.

22. Lee SH, Ryu HY, Song MS, Kang HS, Hong SP, Lee TW, Lim CG, Kim MJ. Left ventricular hypertrophy in end-stage renal disease. Korean J Med. 1998; 55:383–392.

23. Chang T, Park JT, Lee JE, Lee SC, Kim JS, Kim HJ, Ryu DR, Yoo TH, Choi HY, Choi KH, Lee HY, Han DS, Kang SW. The comparison of 99mTc-sestamibi SPECT (MIBI) and echocardiographic findings between diabetic and non-diabetic patients starting dialysis treatment. Korean J Nephrol. 2004; 23:577–585.

24. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995; 47:186–192.

25. Chung SJ, Moon KH, Song IS, Lee MS, Shin YT, Chae DW, Hong CD, Park JS. Cardiac disease and its risk factors in patients starting hemodialysis. Korean J Nephrol. 1999; 18:284–292.

26. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999; 34:125–134.

27. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001; 12:2759–2767.

28. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004; 65:1492–1498.

29. Kim SJ, Oh HJ, Yoo DE, Shin DH, Lee MJ, Kim HR, Park JT, Han SH, Yoo TH, Choi KH, Kang SW. Electrocardiographic left ventricular hypertrophy and outcome in hemodialysis patients. PLoS One. 2012; 7:e35534.

30. US Renal Data System. USRDS 2010 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases;2010.

31. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol. 2003; 14:3270–3277.

32. Yamamoto K, Burnett JC Jr, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, Nakao K, Redfield MM. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996; 28:988–994.

33. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology. 1993; 132:1961–1970.

34. Wang AY, Lai KN. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol. 2008; 19:1643–1652.

35. Roberts MA, Hedley AJ, Ierino FL. Understanding cardiac biomarkers in end-stage kidney disease: Frequently asked questions and the promise of clinical application. Nephrology (Carlton). 2011; 16:251–260.